Knee osteoarthritis (KOA) is a painful joint condition with a global prevalence of more than 300 million. Available treatments include physical therapy and joint replacement surgery. Arthrosamid is an injection that allows those who suffer from KOA to receive minimally invasive treatment that will last long-term. It is given in a minimally invasive outpatient procedure, often performed in clinics.
The global knee reconstruction market is valued at above $10 billion, according to GlobalData. It is expected to continue rising as indications for KOA increase in prevalence. Contura, the manufacturer of Arthrosamid, does not hold a majority market share in the knee reconstruction market. This innovation may give the company a wider reach globally.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
The Observational Clinical Investigation of Arthrosamid in Knee Osteoarthritis (LUNA) trial follows long-term effects of patients who received Arthrosamid, assessing pain, stiffness and physical function. Arthrosamid is currently available in Europe, Canada and New Zealand. One-year results from the LUNA study showed that no patients experienced serious adverse events from treatment. It also showed that pain improved, and side effects quickly subsided. Current results indicate that KOA symptoms improved over one year and that KOA symptoms are relieved for up to three years. Patient progress will continue to be monitored for up to five years.
Minimally invasive treatment that has long-lasting effects could take the strain off hospitals. As more people are diagnosed with KOA, access to minimally invasive outpatient treatment allows more patients to be treated every day.
Minimally invasive treatments, which provide a lower-cost, faster recovery option than many surgeries, will likely be the preferred method of treatment in many different surgical areas. Minimally invasive treatments may also allow for patients to treat KOA earlier, instead of trying many other options that do not provide long-term relief.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
